Evaluation of Discontinuation and Re-Initiation of Biologic Therapies in Psoriasis: Real-World Data - PubMed
3 hours ago
- #Treatment response
- #Psoriasis relapse
- #Biologic therapies
- The cumulative probability of remaining relapse-free after discontinuing biologic therapy for psoriasis decreases over time, with rates of 35.6% at 6 months, 19% at 12 months, 11.6% at 18 months, and 9.1% at 24 months.
- Key factors influencing relapse duration include the class of biologic therapy used (IL-23 inhibitors associated with the longest relapse duration of 38 weeks, followed by IL-12/23, IL-17, and TNF-α inhibitors), baseline PASI score, PASI 90 response at discontinuation, and presence of triggering factors.
- Among patients who restarted biologic therapy after relapse, PASI 90 response rates varied by drug class: TNF-α inhibitors (52.9%), IL-17 inhibitors (78.8%), IL-12/23 inhibitor (76.5%), and IL-23 inhibitors (92.3%).
- Prolonged relapse durations are linked to low baseline PASI scores, achieving PASI 90 response at discontinuation, absence of triggering factors, and use of IL-23 inhibitors.